RET and non-small cell lung carcinoma: The annual BM incidence rates were as follows: wild‐type, 0.13 (95% CI 0.11–0.16); EGFR‐mutant, 0.16 (95% CI 0.11–0.21); ALK‐positive, 0.17 (95% CI 0.10–0.27); KRAS‐mutant, 0.10 (95% CI 0.06–0.17); ROS1‐rearranged, 0.13 (95% CI 0.06–0.28); and RET‐rearranged NSCLC, 0.12 (95% CI 0.08–0.17).